drugset / Trial / NCT02689843
Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS
RandomizedParallel-groupTriple-blindTreatment
Summary
The aim of this study is to evaluate the effects of three-month course of treatment modalities (Cyproterone compound-Spironolactone, Metformin and Pioglitazone) in patients with polycystic ovary syndrome (PCOS) on markers of inflammation \[serum complement, homocysteine and high sensitive C-reactive protein (hs-CRP)\] levels.
Timeline
- Start
- 2018-02-01
- Primary completion
- 2018-11-30
- Completion
- 2018-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metformin | Small molecule | 500 mg | — |
| Comparator | Pioglitazone | Small molecule | 30 mg | — |
| Comparator | Spironolactone | Small molecule | 50 mg | — |
| Comparator | cyproterone acetate | Small molecule | 2 mg | — |
| Comparator | ethinyl estradiol | Small molecule | 35 ug | — |